BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gao J, Gu Z. The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases. Front Pharmacol 2022;13:832732. [DOI: 10.3389/fphar.2022.832732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Ji X, Zhang W, Yin L, Shi Z, Luan J, Chen L, Liu L. The Potential Roles of Post-Translational Modifications of PPARγ in Treating Diabetes. Biomolecules 2022;12. [PMID: 36551260 DOI: 10.3390/biom12121832] [Reference Citation Analysis]
2 Li Y, Cao R, Gu T, Cao C, Chen T, Guan Y, Zhang X. PPARβ/δ Augments IL-1β-Induced COX-2 Expression and PGE2 Biosynthesis in Human Mesangial Cells via the Activation of SIRT1. Metabolites 2022;12:595. [DOI: 10.3390/metabo12070595] [Reference Citation Analysis]
3 Lin Q, Chen O, Wise JP, Shi H, Wintergerst KA, Cai L, Tan Y. FGF1ΔHBS delays the progression of diabetic nephropathy in late-stage type 2 diabetes mouse model by alleviating renal inflammation, fibrosis, and apoptosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2022. [DOI: 10.1016/j.bbadis.2022.166414] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]